The U.S. Federal Trade Commission said on February 17 that the FTC would file a lawsuit aimed at stopping the merger of Rhode Island’s two largest health care providers, Lifespan Corp. and Care New England Health System.
A Johnson & Johnson subsidiary came under attack in court on February 14 for attempting to use the bankruptcy process to resolve tens of thousands of claims that J&J’s baby powder and other talc-based products caused cancer.
Teva Pharmaceutical Industries Ltd. reached a settlement worth $225 million to resolve claims the drugmaker fueled an opioid epidemic in Texas by improperly marketing addictive pain medications, the state’s attorney general said on Feb. 7.
Novo Nordisk on Feb. 2 rejected allegations by a U.S. congressional investigative committee that the company has engaged in maneuvers to increase net prices on life-saving insulin in tandem with its competitors on the U.S. insulin market.
After a U.S. District Court judge ruled that the U.S. Food and Drug Administration must begin disclosing data surrounding the approval of COVID-19 vaccines within a span of eight months, Pfizer hopes to step in to ensure that no trade secrets are disclosed when the regulatory agency begins to share that information.
Malaysian healthcare group IHH Healthcare Berhad said on January 5 Emqore Envesecure Private Capital Trust is seeking in excess of $6.5 billion in damages from it and more than two dozen named defendants in a lawsuit.
Members of the Sackler family on December 6 said billions of dollars they collected from Purdue Pharma before the company filed for Chapter 11 was the result of extra cash, not part of a “secret plan” to abuse the bankruptcy system.
The Oklahoma Supreme Court overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
Johnson & Johnson and Costco Wholesale Corp. reached a tentative agreement to settle lawsuits over the presence of a cancer-causing substance in several recalled J&J sunscreen products.
Johnson & Johnson settled most of the lawsuits the company faced by thousands of men who claimed the anti-psychotic drug Risperdal caused them to develop excessive breast tissue and disclosed that J&J recorded $800 million in expenses in connection with the agreement.
